Literature DB >> 19309322

Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.

Yuichi Ishikawa1, Hitoshi Kiyoi, Akane Tsujimura, Shuichi Miyawaki, Yasushi Miyazaki, Kazutaka Kuriyama, Masao Tomonaga, Tomoki Naoe.   

Abstract

Acute myeloid leukemia (AML) has been thought to be the consequence of two broad complementation classes of mutations: class I and class II. However, overlap-mutations between them or within the same class and the position of TP53 mutation are not fully analyzed. We comprehensively analyzed the FLT3, cKIT, N-RAS, C/EBPA, AML1, MLL, NPM1, and TP53 mutations in 144 newly diagnosed de novo AML. We found 103 of 165 identified mutations were overlapped with other mutations, and most overlap-mutations consisted of class I and class II mutations. Although overlap-mutations within the same class were found in seven patients, five of them additionally had the other class mutation. These results suggest that most overlap-mutations within the same class might be the consequence of acquiring an additional mutation after the completion both of class I and class II mutations. However, mutated genes overlapped with the same class were limited in N-RAS, TP53, MLL-PTD, and NPM1, suggesting the possibility that these irregular overlap-mutations might cooperatively participate in the development of AML. Notably, TP53 mutation was overlapped with both class I and class II mutations, and associated with morphologic multilineage dysplasia and complex karyotype. The genotype consisting of complex karyotype and TP53 mutation was an unfavorable prognostic factor in entire AML patients, indicating this genotype generates a disease entity in de novo AML. These results collectively suggest that TP53 mutation might be a functionally distinguishable class of mutation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19309322     DOI: 10.1111/j.1600-0609.2009.01261.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  15 in total

1.  Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.

Authors:  Todd M Wilson; Irina Maric; Olga Simakova; Yun Bai; Eunice Ching Chan; Nicolas Olivares; Melody Carter; Dragan Maric; Jamie Robyn; Dean D Metcalfe
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

2.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

Review 3.  Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors:  Kelly Faulk; Lia Gore; Todd Cooper
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

4.  The origin and evolution of mutations in acute myeloid leukemia.

Authors:  John S Welch; Timothy J Ley; Daniel C Link; Christopher A Miller; David E Larson; Daniel C Koboldt; Lukas D Wartman; Tamara L Lamprecht; Fulu Liu; Jun Xia; Cyriac Kandoth; Robert S Fulton; Michael D McLellan; David J Dooling; John W Wallis; Ken Chen; Christopher C Harris; Heather K Schmidt; Joelle M Kalicki-Veizer; Charles Lu; Qunyuan Zhang; Ling Lin; Michelle D O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Lucinda A Fulton; Vincent J Magrini; Sean D McGrath; Ryan T Demeter; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd N Wylie; Jason R Walker; Mark A Watson; Sharon E Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Jacqueline E Payton; Jack D Baty; Shashikant Kulkarni; Jeffery M Klco; Michael H Tomasson; Peter Westervelt; Matthew J Walter; Timothy A Graubert; John F DiPersio; Li Ding; Elaine R Mardis; Richard K Wilson
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

5.  Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.

Authors:  James Marvin; Suchitra Swaminathan; Geoffrey Kraker; Amy Chadburn; James Jacobberger; Charles Goolsby
Journal:  Blood       Date:  2011-01-13       Impact factor: 22.113

6.  A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.

Authors:  Katsuya Sakai; Yuichi Ishikawa; Yumiko Mori; Miki Kobayashi; Chisako Iriyama; Yukiyasu Ozawa; Tatsuya Suzuki; Yosuke Minami; Kazuhiro Ishikawa; Norio Kaneda; Tomoki Naoe; Hitoshi Kiyoi
Journal:  Int J Hematol       Date:  2011-01-25       Impact factor: 2.490

7.  Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.

Authors:  R Kihara; Y Nagata; H Kiyoi; T Kato; E Yamamoto; K Suzuki; F Chen; N Asou; S Ohtake; S Miyawaki; Y Miyazaki; T Sakura; Y Ozawa; N Usui; H Kanamori; T Kiguchi; K Imai; N Uike; F Kimura; K Kitamura; C Nakaseko; M Onizuka; A Takeshita; F Ishida; H Suzushima; Y Kato; H Miwa; Y Shiraishi; K Chiba; H Tanaka; S Miyano; S Ogawa; T Naoe
Journal:  Leukemia       Date:  2014-02-03       Impact factor: 11.528

Review 8.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

Review 9.  Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.

Authors:  Gerald B W Wertheim; Elizabeth Hexner; Adam Bagg
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

10.  Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Authors:  Marta Fernandez-Mercado; Bon Ham Yip; Andrea Pellagatti; Carwyn Davies; María José Larrayoz; Toshinori Kondo; Cristina Pérez; Sally Killick; Emma-Jane McDonald; María Dolores Odero; Xabier Agirre; Felipe Prósper; María José Calasanz; James S Wainscoat; Jacqueline Boultwood
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.